CervoMed Stock Soars 63.36% on Positive Dementia Drug Trial Data

On July 28, 2025, CervoMed's stock surged by 63.36% in pre-market trading, marking a significant milestone for the biotech company.

CervoMed recently announced positive 32-week data from the extension phase of its Phase 2b RewinD-LB trial for neflamapimod, a drug aimed at treating dementia with Lewy bodies (DLB). The data showed a 54% reduction in the risk of clinically significant worsening on the CDR-SB scale over the 32-week treatment period. This breakthrough has garnered substantial attention from investors and the medical community alike, highlighting the potential of neflamapimod as a groundbreaking treatment for DLB.

The positive trial results have been a key driver behind the stock's recent surge. The company's presentation of these findings at the Alzheimer's Association International Conference (AAIC) 2025 further solidified investor confidence in CervoMed's innovative approach to treating neurodegenerative diseases. The data not only demonstrated a significant reduction in disease progression but also showed continued biological activity, suggesting long-term benefits for patients.

CervoMed's commitment to advancing its clinical trials and presenting robust data has positioned the company as a leader in the field of dementia research. The positive outcomes from the RewinD-LB trial extension phase have set a strong foundation for future developments, potentially paving the way for regulatory approvals and broader market acceptance.